R&D Nuno Arantes-Oliveira, President of P-BIO, Portugal’s Biotechnology Industry Organization, the country’s sole association for biotechnology companies, discusses the state of the biotech industry today in Portugal, and the ways in which the industry can consolidate and attract overseas investment to stimulate growth. After a harsh economic downturn over the…
Biotechnology Despite Portugal’s economic woes, some local companies have been able to adjust accordingly and succeed in this environment. Tecnifar is no exception. The company’s CEO, António Chaves Costa, talks about Tecnifar’s in-licensing strategy, as well as its diversification of investments and future plans for export business. Last year, Tecnifar…
medical tourism Joaquim Cunha, Executive Director of Health Cluster Portugal (HCP), emphasizes Portugal’s need to discover niches in which the country can excel and compete globally, while rebranding its image around the world. He also highlights the drivers behind cluster’s main initiatives: innovation, collaboration/coopetition and internationalization. What is Portugal’s number one…
R&D The Chairman & CEO of SV More speaks about the path that led him to found the company nearly three decades ago, what changes need to be made in the future in order to maintain the current success of the company, and what aspect of his company makes him the…
R&D Francis del Val, President & Managing Director of GSK, Philippines, talks about his experience working in the pharmaceutical and healthcare sector in the Philippines, and discusses at length the company’s (and industry’s) largest challenge: Employee retention. The growth of the pharmaceutical market, according to IMS Health data, is only set…
R&D John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for growth in Canada still, and his strategy for the company’s international exposure. How did you come to lead HTX and what are the parallels…
R&D Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a wider variety of areas within the industry. What opportunity did you see in moving your career from Pharmascience to Pharmetics? The business opportunity was…
Generics David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and internationally. 2013 marks the thirtieth anniversary of Pharmascience. How does the company’s original business compare with its business today? Pharmascience was first established as…
See our Cookie Privacy Policy Here
